ImmuCell appoints Olivier te Boekhorst as President and CEO effective Nov 1, 2025

IMMUCELL CORP /DE/

Olivier te Boekhorst, former IDEXX Senior VP and Archimed Operating Partner, named CEO.
Current CEO Michael Brigham to become Special Advisor for at least two months and remain on Board.
Base salary of $450,000, annual bonus up to $400,000, $100,000 signing bonus.
Received inducement stock option for 76,673 shares at $5.90; second grant for up to 85,000 shares.
Options vest over three years; options granted Sep 16, 2025 have 10-year term.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.